Crystagen vs Vilon
Moderate Research vs Moderate Research
synergistic Both have immunoprotecting properties; different mechanisms complement each other.
Molecular Data
Crystagen Vilon
Weight 359 Da 275 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes Not established
Chain 3 amino acids 2 amino acids
Type Tripeptide bioregulator Dipeptide bioregulator
Key Benefits
Crystagen
01 Normalizes immune function in 82% of patients
02 Stimulates normal lymphocyte proliferation
03 Inhibits tumor cell growth (antitumor activity)
04 Doubles HSP gene expression (stress resistance)
05 Reduces respiratory viral infections
06 Activates B-cell immune system
07 Normalizes IL-6 expression
08 Effective after radiation/chemotherapy
Vilon
01 Increases mean lifespan 20-40% in animal models
02 Suppresses tumor development
03 Stimulates thymocyte proliferation
04 Activates T-helper cells
05 Restores chromatin structure in aged lymphocytes
06 Enhances intestinal barrier function
07 Improves enzyme activity in aged tissue
08 Part of comprehensive longevity protocols
Dosing Protocols
Crystagen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Vilon
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Crystagen
Generally well-tolerated
Minimal side effects reported
Vilon
Generally well-tolerated
Minimal side effects reported
Contraindications
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Crystagen Vilon
Status Moderate Research Moderate Research
References 4 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.